10 20 30 40 50 60 70 80 1W9N - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER ANTIBIOTIC 14-OCT-04 1W9N
TITLE ISOLATION AND CHARACTERIZATION OF EPILANCIN 15X, A NOVEL TITLE 2 ANTIBIOTIC FROM A CLINICAL STRAIN OF STAPHYLOCOCCUS TITLE 3 EPIDERMIDIS
COMPND MOL_ID: 1; COMPND 2 MOLECULE: EPILANCIN 15X; COMPND 3 CHAIN: A
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: STAPHYLOCOCCUS EPIDERMIDIS; SOURCE 3 ORGANISM_TAXID: 1282; SOURCE 4 STRAIN: 15X150
KEYWDS ANTIBIOTIC, TYPE A LANTIBIOTIC, LANTHIONINE, ANTIBACTERIAL, THIOESTER
EXPDTA SOLUTION NMR
NUMMDL 20
AUTHOR M.EKKELENKAMP,M.G.M.HANSSEN,S.-T.D.HSU,A.DE JONG,D.MILATOVIC, AUTHOR 2 J.VERHOEF,N.A.J.VAN NULAND
REVDAT 5 13-JUL-11 1W9N 1 VERSN REVDAT 4 24-FEB-09 1W9N 1 VERSN REVDAT 3 03-APR-07 1W9N 1 HETATM REVDAT 2 21-APR-05 1W9N 1 LINK REVDAT 1 01-APR-05 1W9N 0
JRNL AUTH M.EKKELENKAMP,M.G.M.HANSSEN,S.-T.D.HSU,A.DE JONG, JRNL AUTH 2 D.MILATOVIC,J.VERHOEF,N.A.J.VAN NULAND JRNL TITL ISOLATION AND STRUCTURAL CHARACTERIZATION OF EPILANCIN 15X, JRNL TITL 2 A NOVEL LANTIBIOTIC FROM A CLINICAL STRAIN OF JRNL TITL 3 STAPHYLOCOCCUS EPIDERMIDIS. JRNL REF FEBS LETT. V. 579 1917 2005 JRNL REFN ISSN 0014-5793 JRNL PMID 15792796 JRNL DOI 10.1016/J.FEBSLET.2005.01.083
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.-T.D.HSU,E.BREUKINK,E.TISCHENKO,M.A.LUTTERS,B.DE KRUIJFF, REMARK 1 AUTH 2 R.KAPTEIN,A.M.J.J.BONVIN,N.A.J.VAN NULAND REMARK 1 TITL THE NISIN-LIPID II COMPLEX REVEALS A PYROPHOSPHATE CAGE REMARK 1 TITL 2 THAT PROVIDES A BLUEPRINT FOR NOVEL ANTIBIOTICS REMARK 1 REF NAT.STRUCT.MOL.BIOL. V. 11 963 2004 REMARK 1 REFN ISSN 1545-9993 REMARK 1 PMID 15361862 REMARK 1 DOI 10.1038/NSMB830 REMARK 1 REFERENCE 2 REMARK 1 AUTH S.-T.D.HSU,E.BREUKINK,B.DE KRUIJFF,R.KAPTEIN,A.M.J.J.BONVIN, REMARK 1 AUTH 2 N.A.J.VAN NULAND REMARK 1 TITL MAPPING THE TARGETED MEMBRANE PORE FORMATION MECHANISM BY REMARK 1 TITL 2 SOLUTION NMR: THE NISIN Z AND LIPID II INTERACTION IN SDS REMARK 1 TITL 3 MICELLES REMARK 1 REF BIOCHEMISTRY V. 41 7670 2002 REMARK 1 REFN ISSN 0006-2960 REMARK 1 PMID 12056898 REMARK 1 DOI 10.1021/BI025679T REMARK 1 REFERENCE 3 REMARK 1 AUTH S.-T.D.HSU,E.BREUKINK,G.BIERBAUM,H.-G.SAHL,B.DE KRUIJFF, REMARK 1 AUTH 2 R.KAPTEIN,A.M.J.J.BONVIN,N.A.J.VAN NULAND REMARK 1 TITL NMR STUDY OF MERSACIDIN AND LIPID II INTERACTION IN REMARK 1 TITL 2 DODECYLPHOSPHOCHOLINE MICELLES. CONFORMATIONAL CHANGES ARE REMARK 1 TITL 3 A KEY TO ANTIMICROBIAL ACTIVITY REMARK 1 REF J.BIOL.CHEM. V. 278 13110 2003 REMARK 1 REFN ISSN 0021-9258 REMARK 1 PMID 12562773 REMARK 1 DOI 10.1074/JBC.M211144200
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS, GROSSE- REMARK 3 KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU,READ, REMARK 3 RICE,SIMONSON,WARREN REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 1W9N COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 18-OCT-04. REMARK 100 THE PDBE ID CODE IS EBI-21321.
REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 283.0 ; 283.0 REMARK 210 PH : NULL ; NULL REMARK 210 IONIC STRENGTH : NULL ; NULL REMARK 210 PRESSURE : 1.0 ; 1.0 REMARK 210 SAMPLE CONTENTS : 10%WATER/90%D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : NOESY, TOCSY, 1H-13C HSQC, REMARK 210 1H-13C HMBC ; NOESY, TOCSY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 ; 750 REMARK 210 SPECTROMETER MODEL : OTHER ; OTHER REMARK 210 SPECTROMETER MANUFACTURER : BRUKER ; BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NMRVIEW REMARK 210 METHOD USED : ARIA REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : LEAST TOTAL ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : NULL REMARK 210 REMARK 210 REMARK: NONE
REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS.
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 400 REMARK 400 COMPOUND REMARK 400 EPILANCIN 15X IS A LINEAR TYPE A LANTIBIOTIC. THE LANTIBIOTICS REMARK 400 ARE CHARACTERIZED BY LANTHIONINE AND/OR METHYLLANTHIONINE REMARK 400 NONPROTEINOGENIC AMINO ACIDS. REMARK 400 HERE, EPILANCIN 15X IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: EPILANCIN 15X REMARK 400 CHAIN: A REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 31 REMARK 400 DESCRIPTION: EPILANCIN 15X IS A TRICYCLIC PEPTIDE. THIOETHER BONDS REMARK 400 WITH CYSTEINE RESULT IN THREE RINGS ALONG THE PEPTIDE REMARK 400 CHAIN. REMARK 400 CROSSLINK 12-16 LANTHIONINE (DAL-CYS) REMARK 400 CROSSLINK 20-23 BETA-METHYLLANTHIONINE (DBB-CYS) REMARK 400 CROSSLINK 22-25 BETA-METHYLLANTHIONINE (DBB-CYS)
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 VAL A 5 116.25 66.27 REMARK 500 1 ALA A 11 170.53 67.96 REMARK 500 1 CYS A 23 -63.09 -92.24 REMARK 500 1 HIS A 26 45.54 -140.70 REMARK 500 2 ALA A 11 99.58 -169.42 REMARK 500 2 LYS A 14 149.58 73.64 REMARK 500 2 LEU A 15 -61.59 75.84 REMARK 500 2 DBB A 20 31.27 -73.89 REMARK 500 2 HIS A 26 93.61 66.16 REMARK 500 3 ALA A 2 -87.47 65.13 REMARK 500 3 LYS A 13 -81.89 61.07 REMARK 500 3 LYS A 14 -56.69 -141.76 REMARK 500 3 CYS A 23 -68.85 -98.56 REMARK 500 4 LYS A 6 34.50 -90.66 REMARK 500 4 DAL A 12 63.33 171.21 REMARK 500 4 LYS A 14 125.91 -173.30 REMARK 500 4 CYS A 16 41.16 -102.00 REMARK 500 4 CYS A 23 -60.88 -106.23 REMARK 500 5 ALA A 11 -165.91 62.68 REMARK 500 5 DAL A 12 74.39 166.42 REMARK 500 5 LEU A 15 76.45 59.68 REMARK 500 5 DBB A 20 45.68 -77.46 REMARK 500 6 LYS A 14 74.87 -161.83 REMARK 500 6 DBB A 20 55.23 132.24 REMARK 500 7 ALA A 11 176.28 63.10 REMARK 500 7 LYS A 13 -58.60 67.71 REMARK 500 7 LYS A 14 -67.19 -130.78 REMARK 500 7 CYS A 16 78.16 45.94 REMARK 500 7 DBB A 20 11.42 142.70 REMARK 500 8 DAL A 12 47.36 139.69 REMARK 500 8 LEU A 15 73.77 -103.48 REMARK 500 8 DBB A 20 38.07 -78.53 REMARK 500 8 LYS A 30 -37.25 74.04 REMARK 500 9 ALA A 2 90.22 62.93 REMARK 500 9 DAL A 12 47.29 178.93 REMARK 500 9 LYS A 13 -50.92 -132.11 REMARK 500 9 HIS A 26 74.00 61.35 REMARK 500 9 PHE A 27 155.81 72.11 REMARK 500 10 DAL A 12 71.22 169.58 REMARK 500 10 CYS A 25 80.10 49.05 REMARK 500 10 HIS A 26 81.77 -155.69 REMARK 500 11 LYS A 6 -174.19 63.28 REMARK 500 11 LYS A 30 -53.57 -120.66 REMARK 500 12 LYS A 10 114.13 64.94 REMARK 500 12 LYS A 13 -75.38 -122.42 REMARK 500 12 LEU A 21 104.59 -58.51 REMARK 500 13 ALA A 2 42.56 -84.17 REMARK 500 13 LYS A 6 81.96 174.58 REMARK 500 13 DAL A 12 -149.86 177.48 REMARK 500 13 LYS A 13 -74.58 169.43 REMARK 500 REMARK 500 THIS ENTRY HAS 80 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AJ1 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE LANTIBIOTIC ACTAGARDINE REMARK 900 RELATED ID: 1MQX RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF TYPE B LANTIBIOTICS MERSACIDIN IN REMARK 900 MEOH/H2O MIXTURE REMARK 900 RELATED ID: 1MQY RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF TYPE B LANTIBIOTICS MERSACIDIN IN REMARK 900 DPC MICELLES REMARK 900 RELATED ID: 1MQZ RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF TYPE B LANTIBIOTICS MERSACIDIN REMARK 900 BOUND TO LIPID II IN DPC MICELLES REMARK 900 RELATED ID: 1QOW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE TUPE B LANTIBIOTIC MERSACIDIN REMARK 900 RELATED ID: 1WCO RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF NISIN AND LIPID II COMPLEX REMARK 900 RELATED ID: 2DDE RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE LANTIBIOTIC CINNAMYCIN COMPLEXED REMARK 900 WITH LYSOPHOSPHATIDYLETHANOLAMINE REMARK 900 RELATED ID: 2KTN RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF LCH-ALPHA PEPTIDE FROM TWO-COMPONENT REMARK 900 LANTIBIOTIC SYSTEM LICHENICIDIN VK21 A1 REMARK 900 RELATED ID: 2KTO RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF LCH-BETA PEPTIDE FROM TWO-COMPONENT REMARK 900 LANTIBIOTIC LICHENICIDIN VK21 A2
DBREF 1W9N A 1 31 UNP P86047 LAN15_STAEP 1 31
SEQRES 1 A 31 2OP ALA DHA ILE VAL LYS DBU DBU ILE LYS ALA DAL LYS SEQRES 2 A 31 LYS LEU CYS ARG GLY PHE DBB LEU DBB CYS GLY CYS HIS SEQRES 3 A 31 PHE DBU GLY LYS LYS
MODRES 1W9N 2OP A 1 SER POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DHA A 3 SER POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DBU A 7 THR POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DBU A 8 THR POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DAL A 12 SER POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DBB A 20 THR POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DBB A 22 THR POST-TRANSLATIONAL MODIFICATION MODRES 1W9N DBU A 28 THR POST-TRANSLATIONAL MODIFICATION
HET 2OP A 1 10 HET DHA A 3 8 HET DBU A 7 11 HET DBU A 8 11 HET DAL A 12 9 HET DBB A 20 12 HET DBB A 22 12 HET DBU A 28 11
HETNAM 2OP (2S)-2-HYDROXYPROPANOIC ACID HETNAM DHA 2-AMINO-ACRYLIC ACID HETNAM DBU (2E)-2-AMINOBUT-2-ENOIC ACID HETNAM DAL D-ALANINE HETNAM DBB D-ALPHA-AMINOBUTYRIC ACID
HETSYN DHA 2,3-DIDEHYDROALANINE HETSYN DBU Z-DEHYDROBUTYRINE
FORMUL 1 2OP C3 H6 O3 FORMUL 1 DHA C3 H5 N O2 FORMUL 1 DBU 3(C4 H7 N O2) FORMUL 1 DAL C3 H7 N O2 FORMUL 1 DBB 2(C4 H9 N O2)
LINK C 2OP A 1 N ALA A 2 1555 1555 1.32 LINK C ALA A 2 N DHA A 3 1555 1555 1.33 LINK C DHA A 3 N ILE A 4 1555 1555 1.32 LINK C LYS A 6 N DBU A 7 1555 1555 1.33 LINK C DBU A 7 N DBU A 8 1555 1555 1.33 LINK C DBU A 8 N ILE A 9 1555 1555 1.32 LINK C ALA A 11 N DAL A 12 1555 1555 1.32 LINK CB DAL A 12 SG CYS A 16 1555 1555 1.80 LINK C DAL A 12 N LYS A 13 1555 1555 1.33 LINK C PHE A 19 N DBB A 20 1555 1555 1.32 LINK CB DBB A 20 SG CYS A 23 1555 1555 1.82 LINK C DBB A 20 N LEU A 21 1555 1555 1.32 LINK C LEU A 21 N DBB A 22 1555 1555 1.33 LINK CB DBB A 22 SG CYS A 25 1555 1555 1.82 LINK C DBB A 22 N CYS A 23 1555 1555 1.31 LINK C PHE A 27 N DBU A 28 1555 1555 1.32 LINK C DBU A 28 N GLY A 29 1555 1555 1.32
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000